Viking Therapeutics Inc (USD)
VKTX
Overview
Key Information
Legal Documents
Financials
Overview
| Sector | Healthcare |
| Industry | - |
| Day Range | 4.31 | 4.58 |
| 52-Wk Range | | |
| Last Close | 4.40 |
| Mkt Cap (m) | 319.28 |
| Dividend yield | - |
| ISIN | US92686J1060 |
| Volume | 917,493 |
| Exchange Venue | NAS |
Company Profile
Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
Key Information
| Price/Earning | - |
| Price/Book | 1.15 |
| Price/Sales | - |
| P/CF | - |
| Rev Growth (3 year avg) | 0.00 |
| EPS Growth (3 year avg) | - |
| Operating Margin % | - |
| Net Margin % | - |
| Return on Equity | -8.97 |
| Debt/Equity | 0.00 |
Documents
Prospectus
| en 02/08/2019 |
Annual Report
| en 31/12/2019 |
Financials
Income Statement
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Revenue (m) | ||||||
| Operating Income (m) | -23 | -12 | -14 | -19 | -26 | -33 |
| Net Income (m) | -22 | -23 | -15 | -21 | -22 | -26 |
| Basic EPS | -7.03 | -3.68 | -0.90 | -0.79 | -0.38 | -0.36 |
| Avg. Diluted Shares Outstanding (m) | 4 | 6 | 16 | 26 | 58 | 72 |
Balance Sheet
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Current Assets (m) | 1 | 15 | 14 | 22 | 302 | 284 |
| Non Current Assets (m) | 2 | 1 | 1 | |||
| Total Assets (m) | 3 | 15 | 15 | 22 | 302 | 284 |
| Current Liabilities (m) | 23 | 2 | 6 | 9 | 5 | 7 |
| Total Liabilities (m) | - | - | - | - | - | - |
| Total Equity (m) | -22 | 9 | 8 | 13 | 298 | 277 |
Cash Flows
| USD | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 |
| Operating Cash Flows (m) | -2 | -9 | -11 | -15 | -19 | -25 |
| Capital Expenditure (m) | - | - | - | - | - | - |
Figures are quoted in USD unless stated otherwise
-
No change
$
4.40
Last Price
© 2019 MeDirect Bank (Malta) plc. All rights reserved.